Key facts
- This page summarizes Laura Shawver's Form 4 filing for ARS Pharmaceuticals, Inc. (SPRY).
- 5 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 08 Apr 2025, 16:45.
Laura Shawver - 07 Apr 2025 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)
- Reporting relationship
- Director
- Issuer ticker
- SPRY
- Reported as of
- 07 Apr 2025
- Net transaction value
- -$372,565
- SEC form
- 4
- Accepted by SEC
- 08 Apr 2025, 16:45:04 UTC
- Prior SEC filing
- 07 Mar 2025
- Next SEC filing
- 27 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kathleen Scott, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Laura Shawver filed Form 4 for ARS Pharmaceuticals, Inc. (SPRY) on 08 Apr 2025.
Change
- Previous filing in this sequence was filed on 07 Mar 2025.
- Current net transaction value: -$372,565.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SPRY
transaction
Common Stock
Options Exercise
- Transaction value
- $109,169
- Shares
- +22,509
- Change %
- +11%
- Price
- $4.85
- Shares after
- 232,855
- Date
- 07 Apr 2025
- Ownership
- Direct
SPRY
transaction
Common Stock
Options Exercise
- Transaction value
- $133,341
- Shares
- +27,493
- Change %
- +12%
- Price
- $4.85
- Shares after
- 260,348
- Date
- 07 Apr 2025
- Ownership
- Direct
SPRY
transaction
Common Stock
Sale
- Transaction value
- $615,075
- Shares
- -50,002
- Change %
- -19%
- Price
- $12.30
- Shares after
- 210,346
- Date
- 07 Apr 2025
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SPRY
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -22,509
- Change %
- -30%
- Price
- $0.000000
- Shares after
- 51,555
- Date
- 07 Apr 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 22,509
- Exercise price
- $4.85
- Footnotes
- F3
SPRY
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -27,493
- Change %
- -53%
- Price
- $0.000000
- Shares after
- 24,062
- Date
- 07 Apr 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 27,493
- Exercise price
- $4.85
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 3 footnotes
Footnote F1
The shares reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024.
Footnote F2
The weighted average sale price for the transaction reported was $12.301 and the range of prices were between $12.0063 and $12.64. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Footnote F3
Immediately exercisable.